Cardiovascular disease is the leading cause of death worldwide. Due to its considerable and growing impact on public health, cardiovascular disease is a crucial focus of our in-house research and development, and has been for decades. In this field, we are currently No. 2 in Europe. We now have 14 therapeutics available, primarily in high blood pressure, heart failure, and venous diseases.
At present, we are pursuing the clinical development of molecular entities in heart failure, stroke, and venous disease complications. In addition, we have partnered with Amgen on the final stage of clinical development of omecamtiv mecarbil, an innovative and promising chronic heart failure treatment. Innovative research programs for the treatment of heart failure in all its forms are underway.
In addition, Wehealth by Servier our eHealth department looks forward to providing patients with innovative eHealth solutions for better care, such as Cardioskin, an intelligent piece of clothing which detects heart rhythm disorders.